Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115846) titled 'Pharmacokinetics and Individualized Dose Optimization of Donafenib in Hepatocellular Carcinoma Patients after Transjugular Intrahepatic Portosystemic Shunt (TIPS)' on Dec. 31, 2025.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Beijing Youan Hospital, Capital Medical University
Condition:
Hepatocellular Carcinoma
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-01-01
Target Sample Size: Observation group:20;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=303335
Disclaimer: Curated by HT Synd...